PLoS ONE · 2015 · 64 citations · 25 references
MedicineOncologyPharmacologyCancer PharmacologyCell SignalingMolecular OncologyCancer Cell SignalingHepatocellular Carcinoma PharmacotherapyMalignant NeoplasmsOncogenic Signaling PathwaysReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsAdjuvant UseAnticancer ActivityCancer Signaling PathwaysHepatocellular Carcinoma PathogenesisIn Vivo StudiesMolecularly Targeted AgentsSorafenib TherapyTumor Cell Survival Pathways
Inhibition of VEGFR2 activity has been proposed as an important strategy for the clinical treatment of hepatocellular carcinoma (HCC). In this study, we identified corosolic acid (CA), which exists in the root of Actinidia chinensis, as having a significant anti-cancer effect on HCC cells. We found that CA inhibits VEGFR2 kinase activity by directly interacting with the ATP binding pocket. CA down-regulates the VEGFR2/Src/FAK/cdc42 axis, subsequently decreasing F-actin formation and migratory activity in vitro. In an in vivo model, CA exhibited an effective dose (5 mg/kg/day) on tumor growth. We further demonstrate that CA has a synergistic effect with sorafenib within a wide range of concentrations. In conclusion, this research elucidates the effects and molecular mechanism for CA on HCC cells and suggests that CA could be a therapeutic or adjuvant strategy for patients with aggressive HCC.
25
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
Sorafenib in Advanced Hepatocellular Carcinoma
재연 정 · 2008 · 5.6K citations
Medicine, Oncology, Pharmacology +12
Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Katharine L. Sackton, Nevena Dimova, Xing Zeng et al. · Nature · 2014 · 263 citations
Zhiyu Wang, Neng Wang, ShouWei Han et al. · PLoS ONE · 2013 · 228 citations · Full text
Medicine, Oncology, Pharmacology +15